These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

8697 related items for PubMed ID: 16904047

  • 1. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J, Jones J, Takeda A, Davidson P, Price A.
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [Abstract] [Full Text] [Related]

  • 2. Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation.
    Jones J, Shepherd J, Baxter L, Gospodarevskaya E, Hartwell D, Harris P, Price A.
    Health Technol Assess; 2009 Jul; 13(35):1-172, iii. PubMed ID: 19607759
    [Abstract] [Full Text] [Related]

  • 3. A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B.
    Takeda A, Jones J, Shepherd J, Davidson P, Price A.
    J Viral Hepat; 2007 Feb; 14(2):75-88. PubMed ID: 17244247
    [Abstract] [Full Text] [Related]

  • 4. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [Abstract] [Full Text] [Related]

  • 5. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W, Yuan H, Mao XR, Deng YD, Chen L.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Comparison of peg-interferon monotherapy to peg-interferon and nucleoside analogue combination therapy for hepatitis B: a meta-analysis of randomized controlled trials].
    Li MY, Yuan XL, Zhang DZ.
    Zhonghua Gan Zang Bing Za Zhi; 2012 Jun; 20(6):442-7. PubMed ID: 23044202
    [Abstract] [Full Text] [Related]

  • 10. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P, Lenci I, Demelia L, Bandiera F, Piras MR, Antonucci G, Nosotti L, Mari T, De Santis A, Ponti ML, Sorbello O, Iacomi F, Angelico M.
    Antivir Ther; 2009 Jun; 14(8):1165-74. PubMed ID: 20032546
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N.
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [Abstract] [Full Text] [Related]

  • 14. Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial.
    Xu Y, Wang X, Liu Z, Zhou C, Qi W, Jiao J, Yu F, Guo H, Zhao P, Wang J.
    BMC Gastroenterol; 2017 Aug 30; 17(1):102. PubMed ID: 28854883
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. HBsAg seroclearance or seroconversion induced by peg-interferon alpha and lamivudine or adefovir combination therapy in chronic hepatitis B treatment: a meta-analysis and systematic review.
    Zhang Y, Chen B, Wang L, Chi J, Song S, Liu M, Zhao Z.
    Rev Esp Enferm Dig; 2016 May 30; 108(5):263-70. PubMed ID: 27023755
    [Abstract] [Full Text] [Related]

  • 17. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S, Coco B, Brunetto MR, Rossetti F, Caputo A, Latour A, Espinos B, Bonino F.
    Antivir Ther; 2013 May 30; 18(4):623-33. PubMed ID: 23486701
    [Abstract] [Full Text] [Related]

  • 18. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N.
    Health Technol Assess; 2007 Mar 30; 11(11):1-205, iii. PubMed ID: 17346498
    [Abstract] [Full Text] [Related]

  • 19. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM, Barbaro G, Francavilla R, Romano M, Barbarini G, Mazzoni E, Mecenate F, Paffetti A, Barlattani A, Struglia C, Villani R, Nauri L, Nosotti L, Armignacco O, Ferri F, Camporiondo MP, Soccorsi F, Club Epatologi Ospedalieri (CLEO) Group.
    Clin Ther; 2008 Feb 30; 30(2):317-23. PubMed ID: 18343270
    [Abstract] [Full Text] [Related]

  • 20. Management of chronic hepatitis B.
    Wilt TJ, Shamliyan T, Shaukat A, Taylor BC, MacDonald R, Yuan JM, Johnson JR, Tacklind J, Rutks I, Kane RL.
    Evid Rep Technol Assess (Full Rep); 2008 Oct 30; (174):1-671. PubMed ID: 19408969
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 435.